Literature DB >> 1695539

Regulation of hepatic cytochrome P-450 during infectious disease.

K W Renton1, L C Knickle.   

Abstract

During episodes of infectious disease the mixed function oxidase system is depressed and the capacity of the liver to metabolize drugs can be compromised in both animals and humans. The depression that occurs during viral infections is mediated via the production of interferon. This action of interferon requires the synthesis of an intermediate protein(s) yet to be identified. Using an oligonucleotide probe for a unique sequence in cytochrome P-450LA omega we have now shown that the mRNA for this isozyme is depressed following the administration of interferon inducers. The magnitude in the loss of mRNA corresponds to the magnitude of the loss in the levels of this isozyme. This depression is observed within 6 h of interferon exposure. It is concluded that the decrease in drug metabolism during viral infections is caused by an interferon-mediated loss in mRNA and subsequent cytochrome P-450 synthesis in the liver.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695539     DOI: 10.1139/y90-119

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  11 in total

Review 1.  Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Authors:  S C Piscitelli; W G Reiss; W D Figg; W P Petros
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

2.  The effect of the acute-phase response on in vitro drug metabolism and plasma protein binding in the horse.

Authors:  P C Mills; J C Ng; D E Auer
Journal:  Vet Res Commun       Date:  1997-07       Impact factor: 2.459

3.  Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450.

Authors:  Alexandra Krauskopf; Timo M Buetler; Nathalie S D Nguyen; Katherine Macé; Urs T Ruegg
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 4.  Role of viral infections in the induction of adverse drug reactions.

Authors:  M Levy
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

5.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

6.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

7.  Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients.

Authors:  Edoardo Giannini; Alberto Fasoli; Federica Botta; Paola Romagnoli; Federica Malfatti; Bruno Chiarbonello; Mario Mamone; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

Review 8.  Allergic adverse reactions to sulfonamides.

Authors:  Geneviève Choquet-Kastylevsky; Thierry Vial; Jacques Descotes
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.919

9.  Elevated Clozapine Blood Concentrations After Second COVID-19 Vaccination With Spikevax (COVID-19 Vaccine Moderna).

Authors:  Christian Knöchel; Gudrun Hefner; Thomas Stiehl; Walter Schmidbauer
Journal:  J Clin Psychopharmacol       Date:  2022-01-28       Impact factor: 3.118

10.  Effects of quercetin on CYP450 and cytokines in Aroclor 1254 injured endometrial cells of the pregnant rats.

Authors:  Lina Xu; Liyun Sun; Liqin Lu; Xiuhui Zhong; Yuzhong Ma; Jianhua Qin
Journal:  Biomed Res Int       Date:  2014-03-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.